Glucose-Regulated Gene Expression Loop for Stable Blood Glucose Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diabetes treatments, such as insulin injections and oral medications, are inadequate for maintaining stable blood glucose levels, leading to risks of hypoglycemia and side effects. Additionally, existing treatments for chronic wounds, like diabetic foot ulcers, are inefficient and often result in adverse side effects.
Innovation Solution
A glucose-regulated gene expression loop control system comprising a transcription repressor HexR, a glucose-induced strong promoter, and a sequence to be transcribed. This system uses a dual-plasmid system to regulate gene expression in response to glucose levels, enabling precise control of blood glucose through the expression of hypoglycemic peptides like GLP-1 and PDX-1.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If insulin injections or oral hypoglycemic drugs are used to control blood glucose, then blood glucose levels can be maintained, but the treatment efficacy is insufficient and causes harmful side effects including hypoglycemia
Solution Approach 1:
The patent employs a glucose-regulated gene expression loop control system where the bacterial cell automatically senses its own glucose concentration and regulates its metabolism accordingly. The system uses a transcription repressor HexR that binds to a promoter region to inhibit gene expression when glucose is low, and releases the repression when glucose is high, enabling the cell to self-regulate glucose metabolism without external intervention
Solution Approach 2:
The patent implements a feedback mechanism where the glucose concentration directly influences gene expression through the HexR repressor. When glucose levels are high, the repressor is released and gene expression increases; when glucose levels are low, the repressor binds and gene expression is inhibited. This creates a self-regulating feedback loop that maintains blood glucose stability and reduces hypoglycemia risk
2Productivity
If standard wound treatment methods are used for chronic wounds, then necrotic tissue can be removed, but the healing process is slow and adverse side effects occur
Solution Approach 1:
The patent uses probiotics as intermediary carriers that can penetrate the wound environment and deliver therapeutic functions. The probiotic bacteria serve as living vehicles that can sense wound conditions through glucose detection and respond by regulating gene expression to produce healing-promoting substances, thereby mediating the interaction between the wound site and the treatment system
Solution Approach 2:
The patent changes the functional parameters of the probiotic bacteria through genetic modification, enabling them to respond to glucose concentration changes by regulating the expression of specific genes. This allows the bacteria to dynamically adjust their metabolic activity and gene expression based on the wound environment, optimizing wound healing while reducing adverse effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system achieves precise regulation of blood glucose levels, reducing the risk of hypoglycemia and enhancing treatment efficacy for diabetes. Additionally, it promotes wound healing by regulating the expression and secretion of growth factors, cytokines, and chemokines in chronic skin wounds.
Implementation Method 1
the transcription repressor HexR can undergo homodimerization and bind to specific DNA sequences
Implementation Method 2
glucose is metabolized through the Entner-Doudoroff pathway to produce the metabolic intermediate 2-keto-3-deoxy-6-phosphogluconate (KDPG)
Data Source
Figure 1~2
Figure 3~5
Figure 6~8
AI summary
Provided are a glucose-regulated gene expression loop control system and use thereof in regulating and controlling blood glucose. The control system comprises a transcription repressor HexR, a glucose-induced strong promoter, and a sequence to be transcribed. Also provided are an expression vector, an engineered cell, a sensor, or a recombinant probiotic comprising the control system and use thereof in preparing a drug for treating diabetes. Further provided are a plasmid, a glucose-induced strong promoter, and a primer pair which are involved in the control system.